UFP Technologies, Inc. (UFPT) is a producer of innovative, custom-engineered components, products, and specialty packaging. Founded in 1963, the company employs a multi-faceted manufacturing strategy across multiple locations in the U.S. and Mexico to meet the needs of its customers. This strategy includes moulding, fabricating, and contract manufacturing services. UFPT is a public company listed on the NASDAQ global market and it has been recognized multiple times for its overall growth, manufacturing capabilities, and environmental stewardiness.
UFP Technologies mainly serves markets in the fields of Automotive, Aerospace & Defense, Medical, Electronics, and Industrial. Their collaborative approach—which allows customers to leverage UFP Technologies’ deep materials expertise and diverse manufacturing capabilities to deliver innovation—is their biggest differentiator. They specialize in creating solutions using materials like foams, plastics, composites, and natural fiber materials.
Some of their notable offerings include the BioShell Suspension Pack, an eco-friendly, single-use solution for shipping temperature-sensitive biopharmaceuticals, and its medical division’s patient positioning solutions, which are designed for minimally invasive surgeries and high-dose radiation therapies.
The company has demonstrated strong growth over the years, showcasing its ability to collaborate with clients and deliver innovative custom solutions. It’s also committed to sustainability through initiatives like reducing energy consumption, minimizing waste, and recycling materials.
UFP Technologies’ vision stretches beyond creating innovative solutions that offer superior performance. They’re also dedicated to building a culture of continuous learning and improvement internally, which further aids in their problem-solving capabilities. Their relentless commitment to provide the highest quality service to customers and to continuously improve and innovate is what has helped UFPT grow from a regional foam fabricator into a diverse manufacturing organization recognised as a leader in the industry.
With over half a century serving industries and clients' needs, UFP Technologies has established a robust reputation for quality and innovative solutions. As industries worldwide continue to evolve, UFPT remains committed to meeting their changing needs through adaptable and sustainable manufacturing processes. Their mission continues to be improving the performance of their customers' products, thus driving their success and fostering lasting relationships.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Federman & Sherwood is investigating a data breach at UFP Technologies Inc. following a notification filed with the California Attorney General. The incident, reported on November 5, 2026, may have compromised sensitive personal information such as names and Social Security numbers. The law firm is examining whether UFP Technologies Inc. implemented adequate cybersecurity safeguards to protect customer data.
Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged following election results that confirmed Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty in the biopharmaceutical sector. Analysts project a strengthened recovery for the industry as drug pricing legislation is unlikely to dominate the new legislative agenda, fostering a predictable regulatory climate. UFP Technologies, in particular, saw a significant jump of 21.5%, contributing to its 51.1% year-to-date increase.
UFP Technologies (NASDAQ:UFPT) shares gapped up after the company reported stronger-than-expected quarterly earnings, with EPS of $2.88 against a $2.49 consensus and revenue of $172.43 million exceeding expectations. Despite the positive earnings, analyst sentiment remains mixed with an average "Hold" rating, and insiders sold a significant number of shares in the last quarter. Institutional investors, however, have significantly increased their positions in the company.
UFP Technologies (NASDAQ: UFPT) is set to announce its Q3 earnings results, with analysts expecting an 8.1% year-on-year revenue growth. The medical products company has a history of beating revenue expectations but has also missed Wall Street's estimates multiple times in the past two years. Investors will be watching closely as other drug development inputs & services segment peers have shown mixed results.
UFP Technologies (UFPT) is expected to report its Q3 2026 earnings after market close on Monday, November 2nd, with analysts forecasting $2.49 EPS on $166.89 million in revenue. This follows a strong previous quarter where the company surpassed expectations with $2.92 EPS and $173.96 million in revenue. Despite a consensus "Hold" rating from analysts, insiders have recently sold over $8.17 million worth of stock.